Comparison of biosimilar Trastuzumab (ABP 980, Kanjinti®) with the Original Antibody (Herceptin®) based on the pCR Rate after neoadjuvant Therapy in early HER2-positive Breast Cancer

被引：0
|
作者：
Matovina, S. [1 ]
Engler, T. [1 ]
Mueller, H. [1 ]
Grischke, E. M. [1 ]
Hahn, M. [1 ]
Brucker, S. Y. [1 ]
Hartkopf, A. D. [1 ]
机构：
[1] Univ Frauenklin Tubingen, Tubingen, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2020年 / 80卷 / 10期
关键词：
D O I：
10.1055/s-0040-1717859
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P027
引用
收藏
页码：E101 / E101
页数：1
相关论文
共 50 条
  • [1] ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer
    Paplomata, Elisavet
    Nahta, Rita
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 335 - 341
  • [2] Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre
    Matovina, Sabine
    Engler, Tobias
    Volmer, Lea-Louise
    Mueller, Heike
    Grischke, Eva-Maria
    Staebler, Annette
    Hahn, Markus
    Brucker, Sara Yvonne
    Hartkopf, Andreas Daniel
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 694 - 701
  • [3] CARDIAC SAFETY OF THE TRASTUZUMAB BIOSIMILAR ABP 980 IN WOMEN WITH HER2-POSITIVE EARLY BREAST CANCER IN THE LILAC STUDY
    Kolberg, H-C
    Colleoni, M.
    Demetriou, G. Sawa
    Santi, P.
    Tesch, H.
    Fujiwara, Y.
    Tomasevic, Z.
    Hanes, V.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A55 - A55
  • [4] Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.
    Kolberg, Hans-Christian
    Colleoni, Marco
    Demetriou, Georgia
    Santi, Patricia Xavier
    Tesch, Hans
    Fujiwara, Yasuhiro
    Tomasevic, Zorica
    Hanes, Vladimir
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
    von Minckwitz, G.
    Ponomarova, O.
    Morales, S.
    Zhang, N.
    Hanes, V.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [7] Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.
    Oukkal, Mohammed
    Challal, Souad
    Benmelha, Nawel Abed
    Benachenhou, Nabil
    Boubnider, Mohcen Wahib
    Kouchkar, Amal
    Terki, Nadia
    Benkhedda, Ghania
    Brahimi, Ghania
    Belkaid, Roza
    Bouzid, Kamel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    [J]. CANCER, 2010, 116 (12) : 2856 - 2867
  • [9] Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
    Kolberg, Hans-Christian
    Colleoni, Marco
    Demetriou, Georgia Savva
    Santi, Patricia
    Tesch, Hans
    Fujiwara, Yasuhiro
    Tomasevic, Zorica
    Hanes, Vladimir
    [J]. DRUG SAFETY, 2020, 43 (03) : 233 - 242
  • [10] Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
    Hans-Christian Kolberg
    Marco Colleoni
    Georgia Savva Demetriou
    Patricia Santi
    Hans Tesch
    Yasuhiro Fujiwara
    Zorica Tomasevic
    Vladimir Hanes
    [J]. Drug Safety, 2020, 43 : 233 - 242
12345